Kornimate/medical-research-clean huggingface dataset:
studying biomarkers in samples from patients with rhabdomyosarcoma

Conditions: Sarcoma

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research trial studies biomarkers in samples from patients with rhabdomyosarcoma.

objectives: * determine whether circulating muscle-specific micrornas, especially serum mir-206, are potential biomarkers for rhabdomyosarcoma (rms). outline: archived serum samples are analyzed for mir-206 expression. projected accrual: a total of 15 samples from patients with alveolar rhabdomyosarcoma (rms), 15 from patients with embryonal rms, and 10 from patients without rms will be accrued for this study.

Eligibility criteria:
disease characteristics: * serum specimens of rhabdomyosarcoma (rms), embryonal rms, and non-rms available from the soft tissue sarcoma committee of children's oncology group patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: embryonal childhood rhabdomyosarcoma adult rhabdomyosarcoma alveolar childhood rhabdomyosarcoma adult soft tissue sarcoma childhood rhabdomyosarcoma
study to test the validity of the treatment of idiopathic pulmonary fibrosis with cotrimoxazole

Conditions: Idiopathic Pulmonary Fibrosis

Summary: first study to test the validity of the treatment of idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with cotrimoxazole. cotrimoxazole may improve the clinical course of the disease through eradication of pneumocystis jiroveci colonization and other mechanisms as inhibiting the activation of alveolar macrophages and producing alterations in the surfactant system which favours the persistent activation of the inflammatory response and the development of pulmonary fibrosis.

idiopathic pulmonary fibrosis (ipf) is a chronic lung disease that is clinically manifested by the appearance of effort dyspnea and impaired lung function. the natural history of the disease is poorly understood and there is no clear consensus as to the most appropriate markers for predicting patient outcome. this pilot controlled trial aims to test the efficacy and safety of cotrimoxazole in the treatment of ipf. this novel therapeutic strategy, with very encouraging preliminary data is based on its pathophysiological basis, primarily related to the elimination of pneumocystis colonization. that elimination, could serve as a potent weapon for reducing morbidity and mortality and the cost associated with this devastating disease.

Eligibility criteria:
inclusion criteria: * patient, regardless of gender, aged 18 to 80 years. * well-established diagnostic criteria of the idiopathic pulmonary fibrosis (ipf) as ata/ers/jrs/alat 2011. * ability to obtain a sample of sputum or oropharyngeal washing. * forced vital capacity (fvc) above 50% from the theoretical value expected. * patient compliance or legal guardian to participate in this study by signing the informed consent. exclusion criteria: * allergy / hypersensitivity or known gastrointestinal intolerance to cotrimoxazole. * use of immunosuppressants or corticosteroids in the previous 90 days at baseline. * exacerbation of ipf and / or pneumonia in the 90 days prior to baseline. * presence of autoimmune diseases or asthma. * patients with other significant diseases other than ipf. it is considered significant disease any disease or condition that, in the investigator's opinion, may jeopardize the patient's health participating in the study or influence the results of the study or the patient's ability to participate in the study. * pregnant or lactating or of childbearing potential not using medically approved contraceptive methods at least three months before or during trial. * participation in another trial with an investigational drug within 30 days or six half-lives (the larger of the two) above the baseline.

Keywords: idiopathic pulmonary fibrosis trimethoprim-sulfamethoxazole pneumocystis jiroveci
study on the safety and efficacy of mr-linac technique in patients with unresectable locally advanced colon cancer

Conditions: Safety and Efficacy

Summary: in this phase i single-arm clinical study, 20 patients with t4b unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with mr-linac with short course radiotherapy (25gy/5f), followed by 4 cycles of mfolfox6 or 3 cycles of xelox chemotherapy, then radical surgical resection, and then postoperatively with 8 cycles of mfolfox6 or 5 cycles of xelox. the study will assess patients' surgical r0 resection rate, pcr or ccr rate, pfs, os, and related adverse effects of treatment, aiming to explore the feasibility, safety, and efficacy of mr-linac in the treatment of unresectable locally advanced colon cancer.


Eligibility criteria:
inclusion criteria: 1. patients over 18 years old 2. patients can remain in a stationary position on the treatment bed for 1-1.5 hours 3. ecog score 0-1 4. pathological diagnosis of colon adenocarcinoma, clinical stage ct4bn0-2m0 5. organ function is normal, and the following conditions are required: white blood cell count ≥3.5×10\^9/l; platelet count ≥100×10\^9/l; hemoglobin ≥90g/l. total bilirubin level ≤1.5× upper limit of normal (uln); ast and alt levels ≤2.5 × uln; endogenous creatinine clearance rate: 56-122ml/min; serum creatinine \<1.0× uln; serum albumin ≥30g/l. 6. able to adhere to the study protocol during the research period 7. signed written informed consent exclusion criteria: 1. patients with dmmr or msi-h 2. presence of other types of tumors in addition to colon adenocarcinoma 3. claustrophobia or inability to undergo mri or treatment due to the presence of metal implants or other reasons 4. distant metastasis (m1) 5. pregnant or lactating women 6. previous anti-tumor treatment 7. concurrent use of prohibited drugs for treatment 8. known history of positive human immunodeficiency virus testing or known acquired immunodeficiency syndrome. 9. clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina pectoris, congestive heart failure (≥new york heart association class ii) or severe arrhythmia requiring medication treatment 10. individuals with uncontrolled epilepsy, central nervous system disorders or a history of mental illness, whose clinical severity may hinder signing informed consent or affect patient compliance with oral medication according to the investigator's judgement 11. organ transplant surgery requiring immunosuppressive therapy 12. severe, uncontrolled recurrent infections or other severe, uncontrolled comorbidities

Keywords: mr-linac unresectable locally advanced colorectal cancer neoadjuvant radiotherapy
retrolaminar block for postoperative analgesia in lumbar herniectomy surgery

Conditions: Postoperative Pain

Summary: this retrospective study included 30 patients scheduled for lumbar herniectomy under general anesthesia. the patients were randomized to receive either retrolaminar block or intravenous analgesia treatment.numeric pain rating scale (nprs) was used to measure the pain intensity of patients in postoperative period. postoperative analgesic requirements were recorded to asses effectiveness of regional anesthesia.opiod and nsai̇d as rescue medication were recorded postoperatively.

this retrospective study included 30 patients scheduled for lumbar herniectomy under general anesthesia. the patients were randomized to receive either rlb or intravenous analgesia treatment. all patients were routinely monitored and their heart rate, blood pressure and pulse oxymetry recorded during the anesthesia. numeric pain rating scale (nprs) scores evaluated at 2, 8, 12, 24 and 48 h after the surgery. opiod and nsai̇d as rescue medication were recorded postoperatively

Eligibility criteria:
inclusion criteria: * patients accepted to part in the study exclusion criteria: * patients not accepted to part in the study * allergic reaction to local anesthetics drugs * lumbar herniectomy of more than two levels

Keywords: retrolaminar block
efficacy and safety study of rtms for upper extremity motor function recovery in ischemic stroke patients

Conditions: Stroke; Hemiplegia

Summary: the purpose of this study is to evaluate efficacy and safety of rtms 『tms』 for upper extremity motor function recovery in patients with ischemic stroke

repetitive transcranial magnetic stimulation (rtms) can modulate the excitability of cortex but exact efficacy and safety of rtms is not well established. eighty four patients will be recruited and will be divided into two groups. each group will receive the real rtms or sham rtms, respectively, over the primary motor cortex of the dominant hand. individual subject will receive ten sessions of rtms. each rtms session is low frequency (1hz), total 1800 stimulations. the purpose of this study is to evaluate efficacy and safety of rtms 『tms』 for upper extremity motor function recovery in patients with ischemic stroke.

Eligibility criteria:
inclusion criteria: * 20-80 yrs old * radiologically confirmed ischemic stroke within 90 days * brunnström stage 3-5 in the affected hand (ischemic stroke-induced hemiplegic side) * patients received stroke treatment and on secondary prevention medication * written informed consent exclusion criteria: * previous medical histories of stroke, cerebral vascular operation, seizure * pregnancy, breastfeeding * patients with hemorrhagic stroke, traumatic brain injury * skin lesion in the stimulation site of scalp * metal implants in the body (cardiac pacemaker or aneurysm clip) * unable to have regular physical and occupational therapies on the affected hand

Keywords: neuronal plasticity transcranial magnetic stimulation stroke upper extremity function recovery
assessment of limb perfusion during junctional tourniquet

Conditions: Bleeding

Summary: the goal of this study is to use contrast enhanced ultrasound to determine the degree to which flow is reduced during application of a junctional tourniquet (jt). contrast enhanced ultrasound is performed to quantify thigh and calf perfusion at baseline and during application of the jt


Eligibility criteria:
inclusion criteria: * healthy subject * age 19-50 exclusion criteria: * peripheral artery disease * known heart failure * right to left shunt * pregnancy * presence of femoral artery aneurysm

Keywords: tourniquet muscle perfusion contrast ultrasound
ciclosporin in the management of new type 1 reactions in leprosy

Conditions: Leprosy

Summary: study 1a: ciclosporin in the management of new type 1 reactions in leprosy objective: a randomised double blind controlled trial comparing ciclosporin and prednisolone,to determine whether treatment with ciclosporin gives the same outcome in the treatment of new type 1 reactions as prednisolone.

we tested our hypothesis that ciclosporin would be as effective as prednisolone in the treatment of patients with leprosy reactions and nerve function impairment and that patients treated with ciclosporin would have fewer side effects than patients treated with prednisolone. a randomised controlled trial comparing ciclosporin and prednisolone in the treatment of acute leprosy t1r was conducted.

Eligibility criteria:
inclusion criteria: * individuals with clinical evidence of t1r with new nerve function impairment (nfi). * aged 18-65 * weigh more than 30kg exclusion criteria: * unwillingness to give informed consent * patients with severe active infections such as tuberculosis * pregnant or breastfeeding women (see appendix ii) * those with renal failure, abnormal renal function, hypertensive * patients taking thalidomide currently or within the last 3 months * patients not willing to return for follow-up * women of reproductive age not willing to use contraception for the duration of the study ( see appendix ii) * hiv positive patients

Keywords: leprosy type 1 reactions prednisolone ciclosporin
serum preptin and amylin levels in polycystic ovary syndrome patients

Conditions: Polycystic Ovary Syndrome

Summary: preptin and amylin are pancreatic hormones which participate in glucose homeostasis. this study aims to evaluate how serum preptin and amylin levels are altered in polycystic ovary syndrome (pcos) patients and healthy women based on bmi groups .

materials and methods: this is a cross-sectional review of 40 pcos patients and 40 healthy women who were matched with respect to bmi (\<25 kg/m2 and ≥25 kg/m2).

Eligibility criteria:
inclusion criteria: the patients with pcos exclusion criteria: cushing's syndrome 21-hydroxylase deficiency congenital adrenal hyperplasia thyroid dysfunction hyperprolactinemia diabetes chronic cardiovascular hepatic, renal, and hematologic diseases malignancies using oral contraceptives, anti-androgens, glucocorticoids, anti-hypertensives, anti-diabetics, calcium supplements and anti-obesity drugs and those who smoke or consume alcohol -

Keywords: amylin; obesity; polycystic ovarian syndrome; preptin
exploratory trial to evaluate the efficacy and safety of d565h twice daily versus d565 once daily

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: exploratory trial to evaluate the efficacy and safety of d565h twice daily versus d565 once daily.

a multi center, randomized, double-blind, parallel design, exploratory trial to evaluate the efficacy and safety of d565h twice daily versus d565 once daily in primary open angle glaucoma or ocular hypertension patients.

Eligibility criteria:
inclusion criteria: 1. more than the age of 19 years old 2. subjects who has primary open-angle glaucoma or ocular hypertension 3. subjects who sign on an informed consent form willingly exclusion criteria: 1. subjects with iop(intraocular pressure) measured at visit 1 and visit 2(am 09:00) above 35 mmhg at more than one eye 2. subjects with a maximum corrected visual acuity of less or than 0.3 in the selected evaluation eye at visit 2 3. subjects who were diagnosed as below with monocular or both eye * acute or chronic closed-angle glaucoma * secondary glaucoma * pseudoexfoliation glaucoma * neovascular glaucoma * aphakia * phacocyst capsular torn intraocular lens 4. subjects with significant eye symptoms/signs(abscesses, diplopia) or severe visual field impairment(mean deviation -25db or more) 5. subjects with severe dry eye syndrome or progressive retinal disease(retinal degeneration, diabetic retinopathy, retinal detachment, macular edema) 6. subjects with inflammatory/infectious eye disease and active eye disease within the last 3 months 7. subjects who have medical history following * glaucoma surgery * subjects with significant history of ocular trauma during the last 6 months, or who underwent surgical ophthalmic surgery * subjects who received topical or systemic steroids within the last 6 months 8. subjects who wore need to wear contact lenses during the study 9. subjects who have drug interaction with the investigational product, have a significant effect on the intraocular pressure, or who may have an effect on the clinical trial results 10. subjects with known hypersensitivity to investigational product 11. women who are nursing, pregnant or planning pregnancy during the study 12. subjects with bronchial asthma or history 13. subjects who have received any other investigational product within 1 month prior to the first dosing 14. impossible subjects who participate in clinical trial by investigator's decision

Keywords: glaucoma, primary open angle ocular hypertension ckd-351
effect of spd422 on platelet lowering and safety in japanese adults with at risk essential thrombocythaemia

Conditions: Essential Thrombocythemia (ET)

Summary: the purpose of this study is to investigate how effective and safe spd422 (anagrelide hydrochloride) is in japanese subjects, diagnosed with essential thrombocythemia, who's previously treatment has either not been effective or has caused unacceptable adverse reactions. the study will aim to show that platelet counts can be safely reduced in treated patients to below 600 x 10\^9/l after a minimum of three months treatment. to demonstrate an positive effect platelet levels will need to remain below 600 x 10\^9/l for at least 4 weeks.


Eligibility criteria:
inclusion criteria: * subjects must have previously been treated with a cytoreductive therapy and been intolerant or refractory to that therapy. exclusion criteria: * subjects should not have any other underlying conditions or medications that would confound the study analysis or interact with the study medication.
the study of massively parallel sequencing in early detection for gynecologic malignant tumor

Conditions: Gynecologic Malignant Tumor

Summary: as human aging, 50% of women will be faced with the threat of cancer, especially gynecological malignancies. ovarian, cervical and endometrial cancer are three major gynecological malignancies. in recent years, the incidence of cervical cancer, especially in young women significantly increased; ovarian cancer, although the incidence of malignant tumors in the female reproductive system ranked second, but its mortality rate already in the first place; and the morbidity and mortality of endometrial cancer is also rising. the key to gynecologic malignancies is how to early diagnose and treat. with the advancement of science and technology, such as molecular biology techniques widely used in the medical field, early diagnosis, proper treatment and other aspects in gynecologic malignancies is expected to achieve a breakthrough. genome-wide scan strategy, making the whole genome for linkage analysis for gynecological malignancies possible. therefore, the investigators intend to find specific mutations to provide a new early screening approach for gynecological malignancies, which in later result in early diagnosis and specific treatment for gynecological malignant tumors.


Eligibility criteria:
inclusion criteria: * female aging from 16 to 75-year old; * preoperative diagnosis of gynecologic malignancies; * have the ability to comply with research programs; * voluntarily participate in the study and signed an informed consent form exclusion criteria: * the cases do not meet the inclusion criteria should be removed from,indicating the reason for excluding.

Keywords: cervical cancer ovarian cancer endometrial cancer high-throughput sequencing
pragmatic randomized trial for arterial catheters in the critical care environment

Conditions: Mechanical Ventilation Complication; Arterial Thrombosis; Limb Ischemia; Shock; Hypotension; Bloodstream Infection; Vasopressor Adverse Reaction; Renal Failure

Summary: investigators will conduct a pragmatic randomized trial to investigate the non-inferiority of restricted use of invasive arterial lines compared to standard arterial line use.

patients in the medical intensive care unit (micu) often receive arterial lines as standard of care, however there are little data to support this practice. investigators will randomly assign consecutive weeks to either current practice(control) or to a more conservative practice of not placing invasive arterial lines except for limited indication indications as defined below (intervention). patients entering during an intervention week will be treated according to the intervention practice throughout their icu stay. likewise, patients entering during a control week will be treated according to current standard practice. permuted block randomization will be used to assure equal numbers of intervention and control weeks. all outcome measures will be obtained through epic data analytics and post-hospitalization phone calls. weekly randomization codes will be generated by the study statisticians and delivered to micu staff via sealed envelopes to be opened at the beginning of each week.

Eligibility criteria:
inclusion criteria: * all subjects admitted to the medical intensive care unit exclusion criterion: * all subjects \<18 years of age.
treatment of post-operative sinonasal polyposis with topical furosemide

Conditions: Nasal Polyps

Summary: prior studies have suggested that topical furosemide may reduce the recurrence of sinonasal polyposis following sinus surgery. this project aims to further investigate that claim through a blinded randomized controlled clinical trial following patients who undergo functional sinus surgery for chronic rhinosinusitis with sinonasal polyposis by randomly assigning participants to receive topical furosemide versus placebo nasal spray for 2 months post operatively. outcomes would be compared at 6 months through endoscopic grading scores using lund kennedy and meltzer scores as well as sino-nasal outcome test (snot-22) scores to measure the rate and degree of recurrence and impact on symptoms in the treatment group versus placebo.


Eligibility criteria:
inclusion criteria: * patients with chronic rhinosinusitis and sinonasal polyposis who are candidates for functional endoscopic sinus surgery exclusion criteria: * hypersensitivity to furosemide or sulfonamides * pregnancy * history of tinnitus * history of sensorineural hearing loss * poorly controlled diabetes * current diuretic therapy * known electrolyte disorder * currently taking aminoglycosides * bun and creatinine levels out of the normal range * history of renal disease * allergy to sulfonamides
diet and hereditary haemorrhagic telangiectasia

Conditions: Hereditary Haemorrhagic Telangiectasia (HHT)

Summary: hereditary haemorrhagic telangiectasia (hht) affects 1 in 5,000 people. the purpose of this study is to provide data regarding the diet and nosebleed frequency using a questionnaire. this will be filled in by people with hht. the questionnaire has been designed in paper format.

hereditary haemorrhagic telangiectasia (hht) affects 1 in 5,000 people, usually causing nosebleeds, skin blood spots, and/or anaemia as a result of bleeding from the nose or gut. the majority of people with hht also have abnormal blood vessels (arteriovenous malformations) in internal organs such as the lungs, liver and brain. management of this multisystem disorder is highly challenging. the lead applicant has spent 20 years working on this rare disease, and identified multiple areas where more evidence is required to assist clinicians and patients with this lifelong condition. a particular issue is whether the diet influences hht or its complications in any way. in this study, people will fill in two questionnaires, one giving details of their diet, and another details of their nosebleeds. they will also be asked to consider participating in an accessory study arm which includes weighing food for one week and providing a food diary, in addition to having a single set of blood test.

Eligibility criteria:
inclusion criteria: * a diagnosis of hereditary haemorrhagic telangiectasia (hht) exclusion criteria: * unable to provide informed consent * presence of another major organ disorder that may affect nutritional status, such as inflammatory bowel disease, or celiac disease.

Keywords: hereditary haemorrhagic telangiectasia nose bleeding iron supplements